



(51) International Patent Classification:

A61K 47/64 (2017.01) C07D 249/16 (2006.01)
 A61K 45/06 (2006.01) C07K 7/50 (2006.01)
 A61K 47/62 (2017.01) C07K 7/52 (2006.01)
 A61P 9/10 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/075535

(22) International Filing Date:

26 August 2022 (26.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/237,627 27 August 2021 (27.08.2021) US
 63/319,957 15 March 2022 (15.03.2022) US

(71) Applicant: **YALE UNIVERSITY** [US/US]; Two Whitney Avenue, New Haven, Connecticut 06510 (US).

(72) Inventors: **CAIANIELLO, David**; c/o Yale Ventures, 433 Temple Street, New Haven, Connecticut 06511 (US). **DERAMON, Edward**; 640 Mix Ave, Apt. 6N, Hamden, Con-

necticut 06514 (US). **SPIEGEL, David**; 321 Blake Circle, Hamden, Connecticut 06417 (US).

(74) Agent: **SILVA, Domingos, J.** et al.; Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102-2186 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS




FIG. 1

(57) Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-piAR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*